MX2015001917A - Composiciones farmaceuticas de memantina. - Google Patents
Composiciones farmaceuticas de memantina.Info
- Publication number
- MX2015001917A MX2015001917A MX2015001917A MX2015001917A MX2015001917A MX 2015001917 A MX2015001917 A MX 2015001917A MX 2015001917 A MX2015001917 A MX 2015001917A MX 2015001917 A MX2015001917 A MX 2015001917A MX 2015001917 A MX2015001917 A MX 2015001917A
- Authority
- MX
- Mexico
- Prior art keywords
- memantine
- dosage forms
- oral dosage
- pharmaceutical compositions
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Abstract
La presente invención se refiere a formas de dosis orales que comprenden memantina o una de sus sales farmacéuticamente aceptables, formulaciones farmacéuticas que comprenden las formas de dosis orales y métodos de tratamiento de demencia por Alzheimer leve, moderada o severa o dolor neuropático que comprenden las formas de dosis orales y formulaciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261683875P | 2012-08-16 | 2012-08-16 | |
US201361833348P | 2013-06-10 | 2013-06-10 | |
PCT/US2013/055420 WO2014028878A1 (en) | 2012-08-16 | 2013-08-16 | Pharmaceutical compositions of memantine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015001917A true MX2015001917A (es) | 2015-10-29 |
Family
ID=49029259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001917A MX2015001917A (es) | 2012-08-16 | 2013-08-16 | Composiciones farmaceuticas de memantina. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20140050784A1 (es) |
EP (1) | EP2884967B1 (es) |
CN (1) | CN104755074A (es) |
AU (1) | AU2013302359A1 (es) |
ES (1) | ES2623176T3 (es) |
IL (1) | IL237139A0 (es) |
IN (1) | IN2015DN01023A (es) |
MX (1) | MX2015001917A (es) |
RU (1) | RU2015107517A (es) |
WO (1) | WO2014028878A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015274456B2 (en) | 2014-06-11 | 2020-03-26 | Massachusetts Institute Of Technology | Self-assembled residence devices and related methods |
US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
CN104586807B (zh) * | 2014-12-25 | 2018-03-30 | 广州帝奇医药技术有限公司 | 用于治疗阿尔茨海默症的缓释制剂及其制备方法 |
CN108472249A (zh) | 2015-10-23 | 2018-08-31 | 林德拉有限公司 | 用于治疗剂缓释的胃驻留系统及其使用方法 |
AU2017336154B2 (en) * | 2016-09-30 | 2023-11-09 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
CN107213130B (zh) * | 2017-05-12 | 2018-05-11 | 上海奥科达生物医药科技有限公司 | 一种恩替卡韦药用组合物、制备方法及其应用 |
EP3741373B1 (en) * | 2018-01-19 | 2022-10-12 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin or active ingredient thereof |
BR112023001663A2 (pt) * | 2020-07-29 | 2023-02-23 | Novamedica Llc | Composição farmacêutica compreendendo memantina e citicolina |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
AU2005265031A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
WO2006089066A1 (en) * | 2005-02-15 | 2006-08-24 | Neuromolecular Pharmaceuticals, Inc. | Combinations therapy for treatment of demyelinating conditions |
AU2006259619A1 (en) | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
TWI491395B (zh) * | 2009-09-30 | 2015-07-11 | Ct Lab Inc | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 |
WO2012101653A2 (en) * | 2011-01-25 | 2012-08-02 | Cadila Healthcare Limited | Modified release pharmaceutical compositions memantine |
TR201104108A2 (tr) * | 2011-04-27 | 2011-08-22 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salımlı memantin tablet. |
-
2013
- 2013-08-16 AU AU2013302359A patent/AU2013302359A1/en not_active Abandoned
- 2013-08-16 MX MX2015001917A patent/MX2015001917A/es unknown
- 2013-08-16 US US13/969,161 patent/US20140050784A1/en not_active Abandoned
- 2013-08-16 CN CN201380054072.8A patent/CN104755074A/zh active Pending
- 2013-08-16 EP EP13752800.6A patent/EP2884967B1/en not_active Not-in-force
- 2013-08-16 RU RU2015107517A patent/RU2015107517A/ru not_active Application Discontinuation
- 2013-08-16 ES ES13752800.6T patent/ES2623176T3/es active Active
- 2013-08-16 IN IN1023DEN2015 patent/IN2015DN01023A/en unknown
- 2013-08-16 WO PCT/US2013/055420 patent/WO2014028878A1/en active Application Filing
-
2015
- 2015-02-08 IL IL237139A patent/IL237139A0/en unknown
-
2017
- 2017-05-01 US US15/583,317 patent/US20170231927A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2623176T3 (es) | 2017-07-10 |
IN2015DN01023A (es) | 2015-06-26 |
US20170231927A1 (en) | 2017-08-17 |
RU2015107517A (ru) | 2016-10-10 |
EP2884967A1 (en) | 2015-06-24 |
CN104755074A (zh) | 2015-07-01 |
AU2013302359A1 (en) | 2015-03-19 |
US20140050784A1 (en) | 2014-02-20 |
IL237139A0 (en) | 2015-04-30 |
EP2884967B1 (en) | 2017-02-01 |
WO2014028878A1 (en) | 2014-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202202711B (en) | Sustained-release dosage forms of ruxolitinib | |
MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
JO3459B1 (ar) | تركيبات صيدلانية لعلاج مرض الزهايمر | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
PH12015502365A1 (en) | Bace1 inhibitors | |
MX347105B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
IN2014MN02236A (es) | ||
UA117154C2 (uk) | Антагоністи s1p3 | |
PH12015501402A1 (en) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
PH12020500120A1 (en) | Pharmaceutical compositions | |
PH12019501070A1 (en) | Sustained-release dosage forms of ruxolitinib | |
WO2016119031A8 (pt) | Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase | |
IN2013MU01152A (es) | ||
GR1007907B (el) | Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης | |
IN2013MU01243A (es) | ||
IN2013MU01245A (es) | ||
IN2013MU01244A (es) | ||
IN2013MU01239A (es) |